Clinical Trial Update: Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating orelabrutinib with obinutuzumab plus FC in newly diagnosed CLL/SLL.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: UNKNOWN